細胞結構。

采用最新進展在測序,ASPE珠數組,微陣列技術,問'Array將提供一係列的DNA測試,包括遺傳、染色體、生物化學、藥物基因組學、親子鑒定,法醫身份測試。

IEP發展biocatalytic(酶)的流程製造高附加值化工或醫藥中間體,降低成本、時間、大量使用有毒溶劑和不必要的產品相比傳統化學。公司目前有13個工業過程在商業運作和提供路線合成的50多個產品。

FlexGen朝著商業化的快速和靈活的定製芯片合成測序基因組選擇的工具和其他應用程序。

螺旋正在尋求治療艾滋病毒/艾滋病和遺傳疾病,如鐮狀細胞性貧血和b-Thalassemia,兩種最常見的人類遺傳疾病。公司的技術,開發出在耶魯大學醫學院的獨家授權,在全球基礎上,螺旋,使用專利寡核苷酸結合人類基因組導致永久性的,有針對性的基因修改(電報)。螺旋的專有的電報技術平台是一種化學遺傳學的方法,使用細胞的DNA修複機製修改永久人類基因體內。

固相生物科學公司收到STTR二期贈款項目的標題為:藥物發現鉛優化芯片的發展。他們獎資助在2009年美國複蘇與再投資法案和他們的項目將解決飼料複合鉛優化芯片的進一步發展和商業化(Multizyme芯片)高通量代鉛化合物的類似物加上細胞篩選生物活性的快速識別衍生品。這種能力直接影響藥物發現的一個關鍵瓶頸;即鉛化合物的高效優化與最優開發藥物藥理性質。固相生物科學公司提出把六個生物催化與生物活性化合物的藥理篩選提供快速識別特異性的目標,這是一個新的範例鉛優化。此外,Multizyme芯片平台將在相關行業,適合領導優化包括農用化學品、化妝品和藥妝品。固相技術將因此提高競爭力和效率的製藥、化妝品、化學工業,將作為豐富的新的和改進的商業產品。這項研究的廣泛影響是固相生物科學的進步將實現向創造更好、更安全的藥物,這些藥物降低開發成本,提高製藥行業的整體效率。固相將生成Multizyme芯片供製藥和生物技術公司,以促進他們的購買鉛優化程序,特別是那些涉及天然product-derived和複雜的合成小分子線索。低溫貯藏技術開發的第二階段將使芯片的銷售和chip-handling設備生產階段,並將允許固相技術平台的無縫滲透進入該公司的目標市場。 Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

羅勒屬Biosolutions生命科學研發使公司三個重點領域,BioIT (LIMS /生物信息學),生物分子和生物學研究。羅勒屬旨在提供端到端基因產品和服務的全球戰略位置,印第安納波利斯(美國),IJsselstien(荷蘭),海德拉巴(印度)。